[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100147826":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":43,"centralContacts":33,"locations":46,"responsibleParty":58,"collaborators":33,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":33,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":33,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":33,"overallStatus":79,"whyStopped":33,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":33,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"BI 10773","EXPERIMENTAL","single oral (high and low) dose per subject",[13,14],"Drug: BI 10773 (low)","Drug: BI 10773 (high)",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo","PLACEBO_COMPARATOR","2 single oral doses per subject",[20],"Drug: BI 10773 Placebo",{"label":22,"type":23,"description":24,"interventionNames":25},"Moxifloxacin","ACTIVE_COMPARATOR","single oral dose per subject",[26],"Drug: Moxifloxacin",[28,34,36,40],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","BI 10773 (low)","single oral dose",[9],null,{"type":29,"name":22,"description":31,"armGroupLabels":35,"otherNames":33},[22],{"type":29,"name":37,"description":38,"armGroupLabels":39,"otherNames":33},"BI 10773 Placebo","2 times single dose",[16],{"type":29,"name":41,"description":31,"armGroupLabels":42,"otherNames":33},"BI 10773 (high)",[9],[44],{"name":5,"affiliation":5,"role":45},"STUDY_CHAIR",[47],{"facility":48,"status":33,"city":49,"state":33,"zip":33,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":33},"1245.16.1 Boehringer Ingelheim Investigational Site","Biberach","Germany","DE",{"type":53,"coordinates":54},"Point",[55,56],8.03333,48.33333,{"lat":56,"lon":55},{"type":59,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100147826","phase-1-assessment-of-the-effect-of-empagliflozin-bi-10773-as-single-dose-on-the-qt-interval-in-healthy-female-and-male-subjects-100147826",true,"NCT01195675","Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects","Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control","Inclusion criteria:\n\nhealthy female and male subjects","ALL","18 Years","55 Years",{"count":71,"type":72},30,"ACTUAL","INTERVENTIONAL",[75],"PHASE1","The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo",[78],"Healthy","COMPLETED","2014-07-25",{"date":82,"type":83},"2014-07-28","ESTIMATED",{"date":85,"type":33},"2010-08",{"name":5,"class":6},1]